{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:26:09Z","timestamp":1789712769235,"version":"4.0.1"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T00:00:00Z","timestamp":1518998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2018,6]]},"abstract":"Summary<\/jats:title>\n \n A government\u2010funded interferon\u2010free direct\u2010acting antiviral (\n DAA<\/jats:styled-content>\n ) treatment programme for chronic hepatitis C virus (\n HCV<\/jats:styled-content>\n ) infection has been available in Australia since March 2016. This study assessed the levels and patterns of\n DAA<\/jats:styled-content>\n treatment uptake during March\u2010December 2016 in Australia and described the key features in the development of the programme. All prescriptions in Australia are submitted to the Pharmaceutical Benefits Scheme by dispensing pharmacies. Data on dispensed\n DAA<\/jats:styled-content>\n prescriptions for a longitudinal cohort of individuals, representing a 10% random sample of the Pharmaceutical Benefits Scheme database, were used for estimating\n DAA<\/jats:styled-content>\n treatment uptake and subgroup analyses. The estimated number of 32\u00a0400 individuals initiated\n DAA<\/jats:styled-content>\n treatment in 2016, equating to 14% of people with chronic\n HCV<\/jats:styled-content>\n infection in Australia. Most commonly prescribed\n DAA<\/jats:styled-content>\n regimens included sofosbuvir\/ledipasvir (56%, n\u00a0=\u00a018\u00a0020), sofosbuvir\u00a0+\u00a0daclatasvir (39%, n\u00a0=\u00a012\u00a0600) and sofosbuvir\u00a0+\u00a0other agents (4%, n\u00a0=\u00a01220). Among individuals initiated\n DAA<\/jats:styled-content>\n treatment, 66% (n\u00a0=\u00a021\u00a0430) were men, 43% (n\u00a0=\u00a013\u00a0870) were \u226450\u00a0years old and 36% (n\u00a0=\u00a011\u00a0670) had cirrhosis.\n DAA<\/jats:styled-content>\n prescriptions were 62% (n\u00a0=\u00a020\u00a0080) by specialists, 19% (n\u00a0=\u00a06000) by general practitioners (\n GP<\/jats:styled-content>\n ) and 20% (n\u00a0=\u00a06320) by other physicians. Proportion of individuals prescribed\n DAA<\/jats:styled-content>\n by\n GP<\/jats:styled-content>\n s increased from 8% to 31% and proportion of individuals \u226450\u00a0years old increased from 28% to 61% between March and December. In conclusion, rapid treatment scale\u2010up was observed in the first 10\u00a0months of unrestricted\n DAA<\/jats:styled-content>\n programme in Australia. The proportion of prescriptions by\n GP<\/jats:styled-content>\n s increased over time, important for broadened access. A trend towards younger age treatment suggested the broadening of\n DAA<\/jats:styled-content>\n \u2010treated population, potentially including individuals at higher risk of\n HCV<\/jats:styled-content>\n transmission.\n <\/jats:p>","DOI":"10.1111\/jvh.12852","type":"journal-article","created":{"date-parts":[[2017,12,24]],"date-time":"2017-12-24T05:37:31Z","timestamp":1514093851000},"page":"640-648","source":"Crossref","is-referenced-by-count":78,"title":["Uptake of direct\u2010acting antiviral treatment for chronic hepatitis C in Australia"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-2028","authenticated-orcid":false,"given":"B.","family":"Hajarizadeh","sequence":"first","affiliation":[{"name":"The Kirby Institute UNSW Sydney Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Grebely","sequence":"additional","affiliation":[{"name":"The Kirby Institute UNSW Sydney Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. V.","family":"Matthews","sequence":"additional","affiliation":[{"name":"The Kirby Institute UNSW Sydney Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Martinello","sequence":"additional","affiliation":[{"name":"The Kirby Institute UNSW Sydney Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J.","family":"Dore","sequence":"additional","affiliation":[{"name":"The Kirby Institute UNSW Sydney Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12253"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ197"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.60"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0406"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(17)30284\u20104"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13453"},{"key":"e_1_2_7_12_1","unstructured":"The Kirby Institute.Hepatitis B and C in Australia Annual Surveillance Report Supplement 2016. Sydney NSW 2052: The Kirby Institute UNSW Australia;2016."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1616-8"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32051-7"},{"key":"e_1_2_7_15_1","first-page":"444A","article-title":"High sustained virological response rates using legally imported, generic direct acting antiviral treatment for hepatitis C","volume":"63","author":"Freeman JA","year":"2016","journal-title":"Hepatology"},{"key":"e_1_2_7_16_1","volume-title":"Global heath strategy on viral hepatitis 2016\u20132021 towards ending viral hepatitis","author":"World Health Organization","year":"2016"},{"issue":"2","key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S2055-6640(20)30895-5","article-title":"Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued","volume":"3","author":"Kwon A","year":"2017","journal-title":"Journal of Virus Eradication"},{"key":"e_1_2_7_18_1","volume-title":"Australian Needle Syringe Program Survey National Data Report 2012\u20132016: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees Sydney","author":"Memedovic S","year":"2017"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)31388-0"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.010"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.025"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000150"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30045-6"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.024"},{"key":"e_1_2_7_25_1","unstructured":"Center for Disease Analysis.Polaris Observatory[Available from:http:\/\/polarisobservatory.com\/polaris\/datasheet.htm."},{"key":"e_1_2_7_26_1","unstructured":"Australian Government Department of Health and Ageing.Fourth National Hepatitis C Strategy 2014\u20132017: Commonwealth of Australia;2014. [http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/ohp-bbvs-hepc."},{"key":"e_1_2_7_27_1","volume-title":"Australian recommendations for the management of hepatitis C virus infection: a consensus statement","author":"Hepatitis C Virus Infection Consensus Statement Working Group","year":"2016"},{"key":"e_1_2_7_28_1","unstructured":"The Kirby Institute UNSW Sydney.Real world efficacy of antiviral therapy in chronic hepatitis C in Australia(Issue 1) Sydney NSW Australia July2017[https:\/\/kirby.unsw.edu.au\/report\/real-world-efficacy-antiviral-therapy-chronic-hepatitis-c-australia-issue-1-July-2017."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.025"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12852","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T13:34:05Z","timestamp":1695476045000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,19]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/jvh.12852"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12852","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,19]]}}}